GLAXO2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member GLAXO2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2019-04-01 2020-03-31 2020-05-11 INR Lakhs Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Unaudited Standalone 7758836000.00 151565000.00 7910401000.00 983289000.00 2012847000.00 -201512000.00 1715845000.00 15075000.00 225852000.00 1507582000.00 6258978000.00 1651423000.00 112679000.00 1764102000.00 579330000.00 -194641000.00 384689000.00 0.00 1379413000.00 0.00 0.00 0.00 0.00 1379413000.00 5325000.00 1384738000.00 1384748000.00 0.00 1694100000.00 10 8.14 8.14 0.00 0.00 8.14 8.14 Notes: n n1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 18th May, 2020. The statutory auditors have not issued a separate limited review report on the results for the quarter ended March 31, 2019. n n2. The figures for the 3 months ended 31st March, 2020 and corresponding 3 months ended 31st March, 2019 are the balancing figures between the audited figures in respect of full financial year and the year to date figures upto the third quarter of the respective financial years. n n3. Effective 1st April, 2019, the Company adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the result for the period(s). n n4.Exceptional items for the year ended 31st March 2020 Rs.32449 lakhs ( year ended 31st March 2019 Rs.489 lakhs) mainly comprise of : na) impacts following the decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India by the Ultimate Holding Company and the comprehensive strategic review of the impact of this recall on all related assets in India: ni. financial impairment of Rs.63743 Lacs (including cost to sell) (year ended 31st March 2019 – Rs. Nil) connected to the under-utilisation of its manufacturing facilities and Rs.9563 Lacs (year ended 31st March 2019 Rs. Nil) on account of other related assets / cost nii. Provisions on account of product recall of Zinetac Rs.10809 lakhs (year ended 31st March 2019 – Rs. Nil) nb) Profit on sale of property Rs. 54630 lakhs (year ended 31st March 2019 Rs. 4339 Lakhs) nc) Impairment of investment held in its wholly owned subsidiary Rs. Nil (year ended 31st March 2019 Rs. 2312 lakhs) nd) Others Rs. 2964 Lacs (year ended 31st March 2019 Rs. 1538 Lacs) n nExceptional items for the quarter ended 31st March 2020 Rs 1127 lakhs (Quarter ended 31st March 2019 Rs. 317 lakhs) mainly comprise of: na)treversal of expense due to settlement/ change in estimate Rs.1127 lakhs (Quarter ended 31st March 2019 Rs Nil) nb)tincome from sale of property Rs. Nil (Quarter ended 31st March 2019 Rs 1995Lacs) nc)timpairment of investment held in its wholly owned subsidiary Rs. Nil ( Quarter ended 31st March 2019 Rs. 2312 lakhs) n nBalance Notes from 5 to 9 have been inserted in Tab Assets Liabilities under- Disclosure of notes on assets and liabilities - Add Notes Single segment 2019-04-01 2020-03-31 Audited Standalone 32246802000.00 775556000.00 33022358000.00 4743797000.00 8689228000.00 -354327000.00 6285535000.00 63355000.00 826777000.00 6298069000.00 26552434000.00 6469924000.00 -3244931000.00 3224993000.00 2601708000.00 -477241000.00 2124467000.00 0.00 1100526000.00 0.00 0.00 0.00 0.00 1100526000.00 -39773000.00 1060753000.00 1060743000.00 0.00 1694100000.00 10 16706337000.00 6.50 6.50 0.00 0.00 6.50 6.50 Other Expenses 1507582000.00 Other Expenses 6298069000.00